Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chimeric Therapeutics Limited (CHMMF) Fair Value & Analysis

Healthcare · US · Market cap $5.5M

Price$0.1000
Fair Value$0.0200
Upside-80.0%
Quality91/100
Evidence: Low Range $0.0100 – $0.0200

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Chimeric Therapeutics Limited (CHMMF) currently trades at $0.1000, while our model-based Fair Value estimate is $0.0200 — implying the stock looks roughly 80.0% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Chimeric Therapeutics Limited (CHMMF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0200 versus a price of $0.1000 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CHMMF?
Our 21-model fair value for Chimeric Therapeutics Limited is $0.0200 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1000.
What is the quality score of CHMMF?
Chimeric Therapeutics Limited has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.